XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently received the CE-IVD approval (European certification) of its 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”). The approval facilitated initial sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East and North America. The company also recently announced delivery of 2,000 units of Covid-ID Lab to an established medical distributor in Israel. This, subject to commercial regulatory approval and subsequent potential product distribution, signaled XPhyto’s entry into the Middle East. “These units will be used for clinical evaluation based on the European CE-IVD approval, one of several international medical device certifications recognized by the Israeli government,” reads a recent article. “The evaluation, expected to be completed within 90 days, will be conducted by the Medical Device Division of the Israeli Ministry of Health (‘AMAR’). ‘We are excited by the opportunity to expand potential distribution beyond Germany,’ said CEO Hugh Rogers. ‘We are building strong partnerships around the world, and Israel is a leading nation for COVID-19 management and research.’”
To view the full article, visit https://ibn.fm/ECOoT
About XPhyto Therapeutics Corp.
XPhyto Therapeutics works with the most promising disrupters in the pharmaceutical industry; accelerates research and technology development; and commercializes products with an entrepreneurial approach and a commitment to efficiency, effectiveness and accessibility. The company’s network spans Europe and North America, with companies at the forefront of diagnostics and drug formulations, and universities specializing in research on the use of psychedelics and cannabinoids. To learn more, visit the company’s website at www.Xphyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
